NASD · Healthcare · Medical Instruments & Supplies · USA
Atricure Inc is a mid cap company (market value between $2 billion and $10 billion) in the Medical Instruments & Supplies industry.
AtriCure develops surgical products for treating atrial fibrillation and managing the left atrial appendage during cardiac procedures. The company also provides cryoablation probes that temporarily block nerve pain signals during cardiac, thoracic, and amputation surgeries. AtriCure distributes its products through direct sales and distributors across the United States, Europe, Australia, and Canada.
From its FY2025 annual report (Form 10-K)
Intrinsic value, DCF valuation, financial health and value investing analysis for the Atricure Inc stock.
Overvalued: intrinsic value $30.98 per share, market price $55.02, margin of safety -77.6% (as of 2026-11-17).
A 2.5x revenue multiple, discounted for its losses, values the shares at $30.98; the price of $55.02 is 78% above that value.
17 more funds hold it; the full list is part of the paid plan.
All 52 Medical Instruments & Supplies stocks
11 more in this industry show a wider margin of safety.
ATRC is overvalued (as of the 2026-11-17 close). A 2.5x revenue multiple, discounted for its losses, values the shares at $30.98; the price of $55.02 is 78% above that value.
$30.98 per share (as of the 2026-11-17 close), against a market price of $55.02. That is a margin of safety of -77.6%. The value comes from the one valuation method that applies to this company, recomputed every night after the US close.